EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway

Jingjing Sun, Yaozu Han, Chen Wang, Tianying Wang, Wenmin Hu, Mengchao Yu, Yixuan Wang, Wei Han

Cellular Signalling · 2026

DOI: 10.1016/j.cellsig.2026.112486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Jingjing Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Qingdao Key Laboratory of Common Diseases, Qingdao Municipal Hospital, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266071, Ch…. Hauptthemen laut MEDLINE: Cisplatin, Carcinoma, Non-Small-Cell Lung, Iridoids, Apoptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Technology Research and Development Program of Shandong, Shandong Province Natural Science Foundation, National Health Commission of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cisplatin-based chemotherapy remains the standard treatment for advanced non-small cell lung cancer (NSCLC); however, its efficacy is constrained by acquired drug resistance and dose-limiting toxicity. Dysregulated apoptosis is recognized as a key mechanism contributing to cisplatin resistance in NSCLC. Geniposide, an active component of traditional Chinese medicine, has demonstrated broad-spectrum antitumor activity; however, its role in cisplatin resistance remains unclear. METHODS: Network pharmacology was employed to identify potential targets. The platinum-resistant A549/DDP cell line and its parental A549 line were used as in vitro models. Functional assays were performed to evaluate proliferation, apoptosis, migration, and mitochondrial membrane potential. RNA sequencing and gene knockdown/overexpression approaches were performed to investigate the underlying molecular mechanisms. An A549/DDP xenograft model was used to assess in vivo therapeutic efficacy. RESULTS: Network pharmacology analysis identified 125 common targets enriched in apoptosis and p53 signaling pathways. Geniposide significantly enhanced cisplatin sensitivity in A549/DDP cells by inhibiting proliferation and migration while promoting apoptosis and inducing mitochondrial membrane potential dissipation. RNA-seq identified PUMA as a key pro-apoptotic mediator. Combined treatment markedly upregulated PUMA expression, accompanied by activation of p53 signaling. Silencing of PUMA or p53 attenuated the chemosensitizing and pro-apoptotic effects, whereas PUMA overexpression independently reduced cisplatin IC₅₀ values. In vivo, geniposide combined with low-dose cisplatin achieved tumor suppression comparable to high-dose cisplatin without inducing systemic toxicity. CONCLUSION: These findings demonstrate that geniposide enhances cisplatin sensitivity in NSCLC by activating the p53-PUMA-mediated mitochondrial apoptotic pathway, thereby providing a potential strategy for overcoming chemotherapy resistance with improved safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinCarcinoma, Non-Small-Cell LungIridoidsApoptosisApoptosis Regulatory ProteinsLung NeoplasmsProto-Oncogene ProteinsHumansAnimalsDrug Resistance, NeoplasmMice, NudeMembrane Potential, MitochondrialCell ProliferationA549 CellsMiceSignal TransductionAntineoplastic AgentsCell MovementCell Line, TumorMice, Inbred BALB CDrug SynergismGene Expression Regulation, NeoplasticXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ApoptosisCisplatin resistanceGeniposideNon-small cell lung cancerPUMA

Substanzen

CisplatinIridoidsgeniposideApoptosis Regulatory ProteinsBBC3 protein, humanProto-Oncogene ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Qingdao Key Laboratory of Common Diseases, Qingdao Municipal Hospital, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266071, China; Department of Respiratory and Critical Care Medicine, Qingdao Mun…
  • Department of Respiratory and Critical Care Medicine, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao 266071, China; NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functio…
  • NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functional Recovery, University of Health and Rehabilitation Science, Qingdao 266071, China; Clinical Research Center, Qingdao Municipal Hospital, University of H…
  • Central Laboratories, Qingdao Municipal Hospital, University of Health and Rehabilitation Science, Qingdao 266071, China. Electronic address: yumengchao2006@163.com.
  • NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functional Recovery, University of Health and Rehabilitation Science, Qingdao 266071, China; Central Laboratories, Qingdao Municipal Hospital, University of Healt…

Förderung

  • Key Technology Research and Development Program of Shandong
  • Shandong Province Natural Science Foundation
  • National Health Commission of the People's Republic of China

Zitieren

APA

Sun, J., Han, Y., Wang, C., Wang, T., Hu, W., Yu, M., Wang, Y., & Han, W. (2026). Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2026.112486

Vancouver

Sun J, Han Y, Wang C, Wang T, Hu W, Yu M, et al. Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2026.112486

BibTeX
@article{Sun2026,
  author = {Sun, Jingjing and Han, Yaozu and Wang, Chen and Wang, Tianying and Hu, Wenmin and Yu, Mengchao and Wang, Yixuan and Han, Wei},
  title = {Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway},
  journal = {Cellular Signalling},
  year = {2026},
  doi = {10.1016/j.cellsig.2026.112486}
}
Kostenlos starten →